Cytokinetics (CYTK) Financial Analysis & Valuation | Quarter Chart
Cytokinetics (CYTK)
CYTKPrice: $87.26
Fair Value: 🔒
🔒score
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle fu... more
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developi... more
Description
Shares
| Market Cap | $10.86B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Robert I. Blum |
| IPO Date | 2004-04-30 | CAGR | — |
| Employees | 673 | Website | www.cytokinetics.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | -0.17% | Total Yield | -0.17% |
CYTK chart loading...
Fundamentals
Technicals
| Enterprise Value | $10.42B | P/E Ratio | -14.97 |
| Forward P/E | -18.68 | PEG Ratio | — |
| P/S Ratio | 117.61 | P/B Ratio | -14.91 |
| P/CF Ratio | -23.53 | P/FCF Ratio | -22.67 |
| EPS | $-5.83 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 450.6% | Gross Margin | 0.9% |
| Operating Margin | -6.05% | Profit Margin | -7.84% |
| ROE | 1.4% | ROA | -0.65% |
| ROCE | -0.6% | Current Ratio | 4.21 |
| Quick Ratio | 4.21 | Cash Ratio | 0.65 |
| Debt/Equity | -1.26 | Interest Coverage | -5.6 |
| Altman Z Score | -2.2 | Piotroski Score | 3 |